<DOC>
	<DOC>NCT01337050</DOC>
	<brief_summary>This is an Asian Phase 1, multi center, open label, single arm study of PF 03446962 with dose escalation and designed to define the Maximum Tolerated Dose [MTD] and the Recommended Phase 2 Dose [RP2D].</brief_summary>
	<brief_title>Asian Phase I Study Of PF-03446962</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Confirmed diagnosis of stomach cancer advanced/metastasis solid tumor refractory or intolerant to established therapy adequate blood chemistry, blood counts and kidney/liver function willing to participate to study requirements and sign an informed consent document Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of first dose of study medication excessive toxicities related to prior therapies pregnant or breastfeeding patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Advanced/Metastatic solid tumors</keyword>
</DOC>